FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy Uterine 4 Mins Read22 On August 1, 2024, the U.S. Food and Drug Administration (FDA) approved an expanded indication for dostarlimab-gxly (Jemperli), in combination…
